McGlone Suttner Wealth Management Inc. Buys 7,784 Shares of Pfizer Inc. (NYSE:PFE)

McGlone Suttner Wealth Management Inc. boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 63.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 20,023 shares of the biopharmaceutical company’s stock after buying an additional 7,784 shares during the period. McGlone Suttner Wealth Management Inc.’s holdings in Pfizer were worth $507,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC raised its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 493 shares during the period. North Capital Inc. bought a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer during the 4th quarter valued at $30,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 0.5%

NYSE:PFE opened at $25.45 on Friday. The firm has a 50 day moving average of $23.72 and a 200 day moving average of $24.82. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The stock has a market capitalization of $144.66 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter last year, the firm earned $0.82 EPS. The business’s quarterly revenue was down 7.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.76%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Redburn Atlantic decreased their target price on Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. HSBC decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a report on Monday, May 19th. TD Cowen dropped their target price on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a research note on Tuesday, April 22nd. Citigroup lifted their price target on shares of Pfizer from $23.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Finally, BMO Capital Markets dropped their price objective on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.